南模生物跌3.17% 2021年上市即巅峰募16.5亿元

Core Viewpoint - Nanmo Bio's stock price has declined, indicating a challenging market response since its IPO, with the company currently in a state of share price depreciation [1][2]. Group 1: Stock Performance - Nanmo Bio's stock closed at 48.21 yuan, reflecting a drop of 3.17% [1]. - The stock reached a peak price of 82.00 yuan on its first trading day, which remains the highest price since its listing [2]. - The company is currently in a "broken" state, meaning its stock price is below the IPO price [2]. Group 2: IPO Details - Nanmo Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an issuance of 19.49 million shares at a price of 84.62 yuan per share [1]. - The total funds raised from the IPO amounted to 1.649 billion yuan, with a net amount of 1.468 billion yuan after deducting issuance costs [2]. - The net funds raised exceeded the original plan by 1.068 billion yuan, with the initial target set at 400 million yuan for various projects [2]. Group 3: Use of Proceeds - The funds raised are intended for several projects, including the establishment of a biological research base, construction of a genetically modified model resource library, development of humanized antibody mouse models, and a drug efficacy platform based on genetically modified animal models, as well as to supplement working capital [2]. Group 4: Issuance Costs - The total issuance costs for the IPO were 181 million yuan, with underwriting and sponsorship fees accounting for 158 million yuan [2].